• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Heartflow Inc.

    3/18/26 4:25:33 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care
    Get the next $HTFL alert in real time by email
    S-8 1 htfl-20260318xs8.htm S-8 2026 S-8

    As filed with the Securities and Exchange Commission on March 18,  2026

    Registration No._________________

    

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ___________________

    FORM S-8

    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

    ___________________

    HEARTFLOW, INC.

    (Exact name of registrant as specified in its charter)

    ___________________

     

     

    Delaware

     

    26-0506743

    (State or other jurisdiction of

     

    (I.R.S. Employer

    incorporation or organization)

     

    Identification No.)

    

    331 E. Evelyn Avenue

    Mountain View, California 94041
    (Address, including zip code, of Principal Executive Offices)

    ___________________

    

    Heartflow, Inc. 

    2025 Performance Incentive Plan

    

    Heartflow, Inc.

    2025 Employee Stock Purchase Plan

     

    (Full title of the plan)

    ___________________

    

    John C.M. Farquhar

    President and Chief Executive Officer

    Heartflow, Inc.

    331 E. Evelyn Avenue

    Mountain View, California 94041

    (650) 241-1221

    (Name, address and telephone number, including area code, of agent for service)

    

    COPY TO: 

    Angela Ahmad

    Heartflow, Inc.

    331 E. Evelyn Avenue

    Mountain View, California 94041

    (650) 241-1221

    

    Shelly Heyduk, Esq.

    Ryan Coombs, Esq.

    O’Melveny & Myers LLP

    610 Newport Center Drive, 17th Floor

    Newport Beach, California 92660

    (949) 823-6900

    ___________________

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. 

    

     

     

    Large accelerated filer  ☐

     

    Accelerated filer  ☐

    Non-accelerated filer  ☑

     

    Smaller reporting company  ☐

    

     

    Emerging growth company  ☑

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.    ☐

    

    

    

     


     

    EXPLANATORY NOTE

    This Registration Statement is filed by Heartflow, Inc., a Delaware corporation (the “Company” or “Registrant”) to register additional securities issuable pursuant to the Heartflow, Inc. 2025 Performance Incentive Plan (the “PIP”) and the Heartflow, Inc. 2025 Employee Stock Purchase Plan (the “ESPP”), and consists of only those items required by General Instruction E to Form S-8.

    The PIP includes an evergreen provision, which provides that the total number of shares reserved for issuance under the PIP (the “Share Limit”) will automatically increase if, on the last day of the fiscal year of the Company, the Share Limit has not increased during such fiscal year pursuant to any Board-approved increase(s) by an aggregate amount equal to or greater than five percent (5%) of the total number of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), outstanding on the first day of such fiscal year (the “Minimum Annual Increase”), then in an amount equal to the difference between the Minimum Annual Increase and the aggregate amount in which the Share Limit increased pursuant to any Board-approved increase(s) during such fiscal year, effective as of the last day of such fiscal year. Notwithstanding the foregoing, the Company’s Board of Directors may act prior to the last day of such fiscal year to provide that an increase in the Share Limit will be a lesser number of shares of Common Stock than would otherwise occur pursuant to the preceding sentence.

    The ESPP also includes an evergreen provision, which provides that the total number of shares reserved for issuance under the ESPP will automatically increase on the first trading day in January of each calendar year during the term of the ESPP by an amount equal to the lesser of (i) one percent (1%) of the total number of shares of Common Stock issued and outstanding on December 31 of the immediately preceding year or (ii) such number of shares of Common Stock as may be established by the Company’s Board of Directors.

    PART I

    INFORMATION REQUIRED IN THE

    SECTION 10(a) PROSPECTUS

    The document(s) containing the information specified in Part I of Form S-8 will be sent or given to participants as specified by Rule 428(b)(1) promulgated under the Securities Act of 1933, as amended (the “Securities Act”).

    2

     


     

    PART II

    INFORMATION REQUIRED IN THE

    REGISTRATION STATEMENT

    Item 3.Incorporation of Certain Documents by Reference

    The following documents of the Company filed with the Securities and Exchange Commission  (the “Commission”) are incorporated herein by reference:

    (a)

    The Company’s Registration Statements on Form S-8, each filed with the Commission on August 11, 2025 (Commission File Nos. 333-289501 and 333-289502);

    (b)

    The Company’s Annual Report on Form 10-K for its fiscal year ended December 31, 2025, filed with the Commission on March 18, 2026 (Commission File No. 001-42790);

    (c)

    The Company’s Quarterly Reports on Form 10-Q for its fiscal quarters ended June 30, 2025 and September 30, 2025, filed with the Commission on September 19, 2025 and November 12, 2025, respectively (each, Commission File No. 001-42790);

    (d)

    The Company’s Current Reports on Form 8-K, filed with the Commission on August 11, 2025 and August 25, 2025 (each, Commission File No. 001-42790 and in each case only as to the information “filed” with the Commission thereunder for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and not as to information “furnished” thereunder); and

    (e)The description of the Company’s Common Stock, filed as Exhibit 4.1 to its Annual Report on Form 10-K for its fiscal year ended December 31, 2025, filed with the Commission on March 18, 2026 (Commission File No. 001-42790), and any other amendment or report filed for the purpose of updating such description.

    All documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with Commission rules shall not be deemed incorporated by reference into this Registration Statement.  Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement.  Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this Registration Statement.

    Item 4.Description of Securities

    Not applicable.

    3

     


     

    Item 5.Interests of Named Experts and Counsel

    The validity of the issuance of Common Stock registered hereby is passed on for the Company by Angela Ahmad.  Ms. Ahmad is the Chief Legal & Compliance Officer of the Company and is compensated by the Company as an employee.  Ms. Ahmad owns 17,944 shares of Common Stock, 51,518 restricted stock units that are payable in an equivalent number of shares of Common Stock, and Company stock options to acquire up to an additional 379,435 shares of Common Stock.  Ms. Ahmad is eligible to receive awards under the PIP and the ESPP. 

    Item 6.Indemnification of Directors and Officers

    Section 145 of the General Corporation Law of the State of Delaware (the “Delaware General Corporation Law”) provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses (including attorneys’ fees), judgments, fines, and amounts paid in settlement actually and reasonably incurred by such person in connection with any threatened, pending, or completed actions, suits, or proceedings in which such person is made a party by reason of such person being or having been a director, officer, employee, or agent to the Registrant. The Delaware General Corporation Law provides that Section 145 is not exclusive of other rights to which those seeking indemnification may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors, or otherwise. Article VIII of the Registrant’s amended and restated certificate of incorporation provides for indemnification by the Registrant of its directors and officers to the fullest extent permitted by the Delaware General Corporation Law. The Registrant has entered into indemnification agreements with each of its current directors, executive officers, and certain other officers to provide these directors and officers additional contractual assurances regarding the scope of the indemnification set forth in the Registrant’s amended and restated certificate of incorporation and to provide additional procedural protections. There is no pending litigation or proceeding involving a director or executive officer of the Registrant for which indemnification is sought.

    Section 102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director or an officer of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or an officer, except for liability (i) for any breach of the director’s or officer’s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) in the case of directors, for unlawful payments of dividends or unlawful stock repurchases, redemptions, or other distributions, or (iv) for any transaction from which the director or officer derived an improper personal benefit; provided that officers may not be indemnified for actions by or in the right of the corporation. The Registrant’s amended and restated certificate of incorporation provides for such limitation of liability.

    The Registrant maintains standard policies of insurance under which coverage is provided (a) to its directors and officers against loss rising from claims made by reason of breach of duty or other wrongful act and (b) to the Registrant with respect to payments that may be made by the Registrant to such officers and directors pursuant to the above indemnification provision or otherwise as a matter of law.

    Item 7.Exemption from Registration Claimed

    Not applicable.

    4

     


     

    Item 8. Exhibits

    See the attached Exhibit Index at page 7, which is incorporated herein by reference.

    Item 9.Undertakings

    (a)The undersigned Registrant hereby undertakes:

    (1)To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i)To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii)To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement;

    (iii)To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

    (2)That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3)To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b)The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c)Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the provisions described in Item 6 above, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.  In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action,

    5

     


     

    suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

    6

     


     

    EXHIBIT INDEX

    

     

     

    Exhibit

    Number

     

    Description of Exhibit

    4.1

     

    Heartflow, Inc. 2025 Performance Incentive Plan. (Filed as Exhibit 10.2 to the Company’s Registration Statement on Form S-1 filed with the Commission on July 17, 2025 (Commission File No. 333-288733) and incorporated herein by this reference).

    4.2

     

    Heartflow, Inc. 2025 Employee Stock Purchase Plan. (Filed as Exhibit 10.3 to the Company’s Registration Statement on Form S-1 filed with the Commission on July 17, 2025 (Commission File No. 333-288733) and incorporated herein by this reference).

    5

     

    Opinion of Counsel (opinion re legality).

    23.1

     

    Consent of PricewaterhouseCoopers LLP (consent of independent registered public accounting firm).

    23.2

     

    Consent of Counsel (included in Exhibit 5).

    24

     

    Power of Attorney (included in this Registration Statement under “Signatures”).

    107

     

    Filing Fee Table.

    

    7

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S‑8 and has duly caused this Form S-8 Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Mountain View, State of California, on March 18, 2026.

    

     

     

     

    

    HEARTFLOW, INC.

    

     

     

     

    

    By:

    /s/ John C.M. Farquhar

    

     

     

    John C.M. Farquhar

    

     

     

    President and Chief Executive Officer

    

     

     

    (Principal Executive Officer)

    

     

     

     

    

     

     

     

    

     

     

     

    

    POWER OF ATTORNEY

    Each person whose signature appears below constitutes and appoints Vikram Verghese, Angela Ahmad and Mhairi L. Jones, and each of them, acting individually and without the other, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments, exhibits thereto and other documents in connection therewith) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them individually, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    

    8

     


     

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

    Signature

     

    Title

     

    Date

    

     

     

     

     

    /s/ John C.M. Farquhar

     

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

     

    March 18, 2026

    John C.M. Farquhar

     

     

    

     

     

     

     

    /s/ Vikram Verghese

     

    Chief Financial Officer

    (Principal Financial Officer)

     

    March 18, 2026

    Vikram Verghese

     

     

    

     

     

     

     

    /s/ Mhairi L. Jones

     

    Chief Accounting Officer

    (Principal Accounting Officer)

     

    March 18, 2026

    Mhairi L. Jones

     

     

    

     

     

     

     

    /s/ William C. Weldon

     

    Chair of the Board of Directors

     

    March 18, 2026

    William C. Weldon

     

     

    

     

     

     

     

    /s/ Timothy C. Barabe

     

    Director

     

    March 18, 2026

    Timothy C. Barabe

     

     

    

     

     

     

     

    /s/ Julie A. Cullivan

     

    Director

     

    March 18, 2026

    Julie A. Cullivan

     

     

    

     

     

     

     

    /s/ Jeffrey C. Lightcap

     

    Director

     

    March 18, 2026

    Jeffrey C. Lightcap

     

     

    

     

     

     

     

    /s/ Wayne J. Riley, M.D.

     

    Director

     

    March 18, 2026

    Wayne J. Riley, M.D.

     

     

    

     

     

     

     

    /s/ Casey M. Tansey

     

    Director

     

    March 18, 2026

    Casey M. Tansey

     

     

    

     

     

     

     

    

    9

     


    Get the next $HTFL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HTFL

    DatePrice TargetRatingAnalyst
    1/28/2026$38.00Overweight
    Wells Fargo
    9/2/2025$36.00Overweight
    Analyst
    9/2/2025$38.00Overweight
    Piper Sandler
    9/2/2025$35.00Buy
    Stifel
    9/2/2025$35.00Buy
    Canaccord Genuity
    9/2/2025$35.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $HTFL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Barabe Timothy C exercised 8,667 shares at a strike of $2.22, increasing direct ownership by 5% to 179,521 units (SEC Form 4)

    4 - Heartflow, Inc. (0001464521) (Issuer)

    3/12/26 7:57:43 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Farquhar John C.M. was granted 2,631 shares and sold $290,886 worth of shares (12,837 units at $22.66), decreasing direct ownership by 2% to 581,450 units (SEC Form 4)

    4 - Heartflow, Inc. (0001464521) (Issuer)

    3/12/26 7:55:55 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Director Cullivan Julie A sold $228,050 worth of shares (9,122 units at $25.00), decreasing direct ownership by 25% to 27,291 units (SEC Form 4)

    4 - Heartflow, Inc. (0001464521) (Issuer)

    3/6/26 8:18:44 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    SEC Filings

    View All

    SEC Form S-8 filed by Heartflow Inc.

    S-8 - Heartflow, Inc. (0001464521) (Filer)

    3/18/26 4:25:33 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Heartflow Inc.

    10-K - Heartflow, Inc. (0001464521) (Filer)

    3/18/26 4:17:46 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Heartflow Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Heartflow, Inc. (0001464521) (Filer)

    3/18/26 4:02:49 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lightcap Jeffrey C bought $1,053,680 worth of shares (40,000 units at $26.34) (SEC Form 4)

    4 - Heartflow, Inc. (0001464521) (Issuer)

    12/17/25 6:43:50 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Heartflow Reports Fourth Quarter and Full Year 2025 Financial Results

    MOUNTAIN VIEW, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Highlights Total revenue of $49.1 million, a 40% increase year-over-yearGross margin of 79.5%, non-GAAP gross margin of 79.9%Net operating loss of $17.8 million, non-GAAP net operating loss of $12.5 millionU.S. installed base of 1,465 accounts as of December 31, 2025U.S. Plaque installed base of 489 accounts as of December 31, 2025Aetna began coverage of Heartflow Plaque Analysis, bringing total U.S. covered lives

    3/18/26 4:01:00 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Heartflow to Participate in the Morgan Stanley Technology, Media & Telecom Conference

    MOUNTAIN VIEW, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Morgan Stanley Technology, Media & Telecom Conference. The presentation will take place in San Francisco, CA, on Tuesday, March 3, 2026, at 10:45 a.m. PT / 1:45 p.m. ET. A live and archived version of the fireside chat will be available on the Investor Relations section of the Heartflow website at https://ir.heartflow.com. About Heartflow's Technology and ResearchHeartflow's technology is redefining precision cardiovascular care throu

    2/18/26 4:05:00 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Heartflow to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026

    MOUNTAIN VIEW, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the fourth quarter and full year of 2025 after market close on Wednesday, March 18, 2026. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on March 18, 2026. Those interested in listening to the conference call should register online using this link. Once registered, participants will receive dial-in numbers and a unique PIN to join the call. Participants are encouraged to register more than 15 minutes prior to the s

    2/13/26 4:21:56 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Heartflow with a new price target

    Wells Fargo initiated coverage of Heartflow with a rating of Overweight and set a new price target of $38.00

    1/28/26 7:17:09 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Analyst initiated coverage on Heartflow with a new price target

    Analyst initiated coverage of Heartflow with a rating of Overweight and set a new price target of $36.00

    9/2/25 8:38:06 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Piper Sandler initiated coverage on Heartflow with a new price target

    Piper Sandler initiated coverage of Heartflow with a rating of Overweight and set a new price target of $38.00

    9/2/25 8:37:45 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    Leadership Updates

    Live Leadership Updates

    View All

    Heartflow Expands GAMEFILM Registry to NBA and NHL Alumni, Precisely Measuring Heart Disease Risk in Former Professional Athletes

    MOUNTAIN VIEW, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced a significant expansion of its groundbreaking GAMEFILM Registry. Building on a successful initial phase enrolling retired National Football League (NFL) athletes, the study will now extend to include former players from the National Basketball Association (NBA) and the National Hockey League (NHL), broadening Heartflow's initiative to protect the heart health of professional athletes across major sports. Retired NBA star Muggsy Bogues was one of the first former professional basketball players to join the GAMEFILM

    2/12/26 8:00:00 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    Financials

    Live finance-specific insights

    View All

    Heartflow Reports Fourth Quarter and Full Year 2025 Financial Results

    MOUNTAIN VIEW, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Highlights Total revenue of $49.1 million, a 40% increase year-over-yearGross margin of 79.5%, non-GAAP gross margin of 79.9%Net operating loss of $17.8 million, non-GAAP net operating loss of $12.5 millionU.S. installed base of 1,465 accounts as of December 31, 2025U.S. Plaque installed base of 489 accounts as of December 31, 2025Aetna began coverage of Heartflow Plaque Analysis, bringing total U.S. covered lives

    3/18/26 4:01:00 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Heartflow to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026

    MOUNTAIN VIEW, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the fourth quarter and full year of 2025 after market close on Wednesday, March 18, 2026. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on March 18, 2026. Those interested in listening to the conference call should register online using this link. Once registered, participants will receive dial-in numbers and a unique PIN to join the call. Participants are encouraged to register more than 15 minutes prior to the s

    2/13/26 4:21:56 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Heartflow to Report Third Quarter 2025 Financial Results on November 12, 2025

    MOUNTAIN VIEW, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the third quarter of 2025 after market close on Wednesday, November 12, 2025. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on November 12, 2025. Those interested in listening to the conference call should register online using this link. Once registered, participants will receive dial-in numbers and a unique PIN to join the call. Participants are encouraged to register more than 15 minutes prior to the start of t

    10/23/25 4:05:00 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care